NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

We know that AI is vital for the NHS to deliver reduced waiting times and faster diagnoses for patients, which is why the health service plays such a vital role in supporting technologies like DERM by ...

We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The following considerations around implementing the evidence generation process have been identified through working with system partners: ...

There is a simple discount patient access scheme for brentuximab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome has been conditionally recommended for NHS use. These cookies remember information that ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...